Back to discover
Drug

Apelin

In clinical development
ClassApelin receptor agonistEmerging researchEarly-to-mid development

Also known as APJ endogenous ligand.

RxNorm1940965ChEMBLCHEMBL4650373UNII7P5ZL6T59Y
3
Research papers
Apelin receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus

Clinical trial2025-09-01Primary completion · ClinicalTrials.gov

Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD- the ESCAPE Study

Clinical trial2025-03-18Completed · ClinicalTrials.gov

Impact of Smoking and Obesity on the Selected Peptide Hormones and Metabolic Parameters in the Blood of Women with Polycystic Ovary Syndrome-Preliminary Study.

Research2024-08-09International journal of molecular sciences

Targeting the apelin system for the treatment of cardiovascular diseases.

Research2023-12-01Cardiovascular research

Beneficial effects of Apelin-13 on metabolic diseases and exercise.

Research2023-11-28Frontiers in endocrinology

Influence of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers

Clinical trial2017-04-01Completed · ClinicalTrials.gov

Cardiovascular Effects of Apelin In Healthy Volunteers

Clinical trial2015-05-01Completed · ClinicalTrials.gov

Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

Clinical trial2014-10-01Completed · ClinicalTrials.gov

Investigating the Acute Pulmonary Vascular Haemodynamic Effects of Apelin in Pulmonary Hypertension

Clinical trial2014-01-01Primary completion · ClinicalTrials.gov

Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure

Clinical trial2012-07-01Completed · ClinicalTrials.gov

Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

Clinical trial2010-05-01Completed · ClinicalTrials.gov

Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man

Clinical trial2010-05-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Apelin
Aliases & brands
APJ endogenous ligand
RxNorm CUI
1940965
ChEMBL ID
CHEMBL4650373
UNII
7P5ZL6T59Y
Primary mechanism
Apelin receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Apelin receptor
APLNR · P35414
AGONISTApelin receptor agonist

Clinical trials

9 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
9
registered trials across all phases
LATEST COMPLETION 2025
5
Late-stage (III+)
7
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 9
Early Phase 11Phase 12Phase 21Phase N / A5

Recent completions

Trials that read out recently, adding to the completed evidence base.

Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD- the ESCAPE Study

CompletedN/AUniversity Hospital, Basel, Switzerlandn=152025

Influence of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers

CompletedPH IUniversity Hospital, Toulousen=92017

Cardiovascular Effects of Apelin In Healthy Volunteers

CompletedPH IUniversity of Edinburghn=142015

Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

CompletedPH IUniversity Hospital, Toulousen=162014

Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure

CompletedN/AUniversity of Edinburghn=242012

Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man

CompletedN/AUniversity of Edinburghn=122010

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major research themes8
Apelin1Cardiovascular Diseases1Cardiovascular System1Chemokines1Intercellular Signaling Peptides and Proteins1Metabolic Diseases1Obesity1Peptide Hormones1
Journals, researchers & institutions
Top journals
  • Cardiovascular research1
  • Frontiers in endocrinology1
  • International journal of molecular sciences1
Leading researchers
  • Bizoń A1
  • Chapman FA1
  • Cheng Y1
  • Davenport AP1
  • Dhaun N1
  • Franik G1
  • Huang R1
  • Maguire JJ1
Leading institutions
free-text, unnormalised
  • Addenbrooke's Centre for Clinical Investigation1
  • BHF/University of Edinburgh Centre for Cardiovascular Science1
  • Medical University of Silesia1
  • Royal Infirmary of Edinburgh1
  • School of Physical Education1
  • School of Sports Health1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Insulin

Studied across 3 of the same disease areas as Apelin in the shared literature.

3 shared diseases1 shared paper
Testosterone

Studied across 3 of the same disease areas as Apelin in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials